BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...Phase III trial of Waylivra to treat familial partial lipodystrophy. Its pipeline includes other wholly-owned programs, AKCEA-APOCIII-LRx...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Retrotransposons as acute myelogenous leukemia targets

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Targeting LTR2B and the related LTR2, both long terminal repeat retrotransposons, could treat AML by reducing expression of the lipoprotein component APOCI. Analysis of a The Cancer...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...program to treat acute pancreatitis induced by high triglycerides. That therapy mimics APOCII while antagonizing APOCIII...
...was approved last year as Rybelsus. Targets APOCII (APOC2) - Apolipoprotein C-II APOCIII (APOC3) - Apolipoprotein C-III...
BioCentury | Jan 23, 2020
Clinical News

Akcea, Ionis Phase II hypertriglyceridemia data hint at improved safety for conjugated antisense therapy

...Akcea and Ionis announced plans to develop AKCEA-APOCIII-LRx for familial chylomicronemia syndrome based on Phase II...
...in the U.S. for FCS. Akcea Therapeutics Inc. (NASDAQ:AKCA) already markets Waylivra volanesorsen, an unconjugated APOCIII...
...APOCIII (APOC3) - Apolipoprotein C-III; LPA - Lipoprotein(a) Sandi Wong, Assistant Editor Ionis Pharmaceuticals Inc. Akcea Therapeutics Inc. Apolipoprotein C-III (APOCIII) (APOC3...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

...disease. Novartis turns down an Akcea cardiovascular product Novartis AG (NYSE:NVS; SIX:NOVN) declined to option AKCEA-APOCIII-LRx...
...by the Swiss pharma. Ionis and Akcea are co-developing the ligand conjugated antisense oligonucleotide targeting APOCIII...
...for continuous release of the chemotherapy gemcitabine. Terms were not disclosed. Targets: APOCIII (APOC3) - Apolipoprotein C-III...
BioCentury | Nov 27, 2019
Company News

With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

...pivotal. Two more candidates are due to begin pivotal studies next year: ARO-APOC3, which targets APOCIII...
...in revenues. Targets: AAT (A1AT; SERPINA1) - α-1 antitrypsin; ANGPTL3 - Angiopoietin-like 3; APOCIII (APOC3) Apolipoprotein C-III...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

...remain in Akcea's pipeline. Data are due next half from a Phase II study of AKCEA-APOCIII-LRx...
...AKCEA-TTR-LRx to treat transthyretin amyloidosis (ATTR). Novartis holds an option on the former program targeting APOCIII...
...Quiver" ). Targets: ANGPTL3 - Angiopoietin-like 3; APOA1 (apo(a)) - Apolipoprotein A-1; APOCIII (APOC3) - Apolipoprotein C-III...
BioCentury | Sep 24, 2019
Company News

Unexpected shakeup at Akcea comes amid drug launches

...our pipeline.” Akcea said it plans to begin Phase III testing shortly of hypertriglyceridemia therapy AKCEA-APOCIII-LRx...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

...is already one approved therapy for the indication. Akcea’s Waylivra volanesorsen, an antisense inhibitor of APOCIII...
...Silver Spring, Md. Targets ANGPTL3 - Angiopoietin-like 3 APOB-100 - Apolipoprotein B-100 APOCIII - Apolipoprotein C-III (APOC3...
BioCentury | Aug 7, 2019
Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

...endpoint in the Phase II/III BROADEN study. On a secondary endpoint, the antisense inhibitor of APOCIII...
...age-related macular degeneration. OPT-302 is a soluble form of human FLT4. Targets: APOCIII (APOC3) - Apolipoprotein C-III...
...KU-0059436, MK-7339) OPT-302, vgx-300 Oraxol Akcea Therapeutics Inc. AstraZeneca plc Athenex Inc. Ionis Pharmaceuticals Inc. Karolinska Institute Merck & Co. Inc. Opthea Ltd. Apolipoprotein C-III (APOCIII) (APOC3) Poly(ADP-ribose...
Items per page:
1 - 10 of 109